Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.
Gerds AT, Harrison C, Kiladjian JJ, Mesa R, Vannucchi AM, Komrokji R, Bose P, Kremyanskaya M, Mead AJ, Gotlib J, Rose S, Sanabria F, Marsousi N, Giuseppi AC, Jiang H, Palmer JM, McCaul K, Ribrag V, Passamonti F. Gerds AT, et al. Among authors: ribrag v. Blood Adv. 2024 Sep 10;8(17):4511-4522. doi: 10.1182/bloodadvances.2024012939. Blood Adv. 2024. PMID: 38820422 Free PMC article.
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators. Mateos MV, et al. Among authors: ribrag v. Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18. Lancet Haematol. 2019. PMID: 31327687 Clinical Trial.
A Phase 2 study of acimtamig (AFM13) in patients with CD30-positive, relapsed or refractory peripheral T-cell lymphomas.
Kim WS, Shortt J, Zinzani PL, Mikhailova N, Radeski D, Ribrag V, Domingo Domenech E, Sawas A, Alexis K, Emig M, Elbadri R, Hajela P, Ravenstijn P, Pinto S, Garcia L, Overesch A, Pietzko K, Horwitz S. Kim WS, et al. Among authors: ribrag v. Clin Cancer Res. 2024 Nov 12. doi: 10.1158/1078-0432.CCR-24-1913. Online ahead of print. Clin Cancer Res. 2024. PMID: 39531538
Relevance, Risks, and Benefits of Early-Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023.
Guerra M, Alouani E, Hueso T, Ouali K, Danu A, Hollebecque A, Bahleda R, Willekens C, Gazzah A, Baldini C, Postel-Vinay S, Micol JB, Massard C, De Botton S, Ribrag V, Michot JM. Guerra M, et al. Among authors: ribrag v. Eur J Haematol. 2024 Sep 21. doi: 10.1111/ejh.14307. Online ahead of print. Eur J Haematol. 2024. PMID: 39305190
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.
Zelenetz AD, Jurczak W, Ribrag V, Linton K, Collins GP, Jiménez JL, Bishton M, Dholaria B, Mengarelli A, Phillips TJ, Sungala N, Musuraca G, Sheehy O, Van Den Neste E, Odera M, Miao L, Gold DP, Ghalie RG, Zinzani PL. Zelenetz AD, et al. Among authors: ribrag v. Hemasphere. 2024 Aug 6;8(8):e138. doi: 10.1002/hem3.138. eCollection 2024 Aug. Hemasphere. 2024. PMID: 39108321 Free PMC article.
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
Géraud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, Stoclin A, Danlos FX, Hollebecque A, Ribrag V, Gazzah A, Goldschmidt V, Baldini C, Suzzoni S, Bahleda R, Besse B, Barlesi F, Lambotte O, Massard C, Marabelle A, Castilla-Llorente C, Champiat S, Michot JM. Géraud A, et al. Among authors: ribrag v. Eur J Cancer. 2024 Jul;205:114075. doi: 10.1016/j.ejca.2024.114075. Epub 2024 May 4. Eur J Cancer. 2024. PMID: 38733717 Review.
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Maris M, Salles G, Kim WS, Kim TM, Lyons RM, Arellano M, Karmali R, Schiller G, Cull E, Abboud CN, Batlevi C, Kagiampakis I, Rebelatto MC, Lee Y, Kirby LC, Wang F, Bothos J, Townsley DM, Fathi AT, Ribrag V. Maris M, et al. Among authors: ribrag v. Target Oncol. 2024 May;19(3):321-332. doi: 10.1007/s11523-024-01054-z. Epub 2024 Apr 29. Target Oncol. 2024. PMID: 38683495 Free PMC article. Clinical Trial.
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.
Fischer L, Jiang L, Dürig J, Schmidt C, Stilgenbauer S, Bouabdallah K, Solal-Celigny P, Scholz CW, Feugier P, de Wit M, Trappe RU, Hallek M, Graeven U, Hänel M, Hoffmann M, Delwail V, Macro M, Greiner J, Giagounidis AAN, Dargel B, Durot E, Foussard C, Silkenstedt E, Weigert O, Pott C, Klapper W, Hiddemann W, Unterhalt M, Hoster E, Ribrag V, Dreyling M. Fischer L, et al. Among authors: ribrag v. Leukemia. 2024 Jun;38(6):1307-1314. doi: 10.1038/s41375-024-02254-2. Epub 2024 Apr 27. Leukemia. 2024. PMID: 38678093 Free PMC article. Clinical Trial.
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.
Sarkozy C, Callanan M, Thieblemont C, Obéric L, Burroni B, Bouabdallah K, Damaj G, Tessoulin B, Ribrag V, Houot R, Morschhauser F, Griolet S, Joubert C, Cacheux V, Delwail V, Safar V, Gressin R, Cheminant M, Delfau-Larue MH, Hermine O, Macintyre E, Le Gouill S. Sarkozy C, et al. Among authors: ribrag v. Blood. 2024 Jul 18;144(3):262-271. doi: 10.1182/blood.2024023944. Blood. 2024. PMID: 38669626 Clinical Trial.
302 results